Figures & data
Table 1.
Summary of currently available monotherapies for VL*.
Table 2.
TPP for new clinical entities against VL (as monotherapy)*.
Table 3.
Potential regimens of LAMB that have been developed for use against VL*.
Box 1.
Review of LAMB treatment for cutaneous, mucosal and post-kala azar leishmaniasis as leishmaniasis also refer back to cutaneous and mucosal.
Table 4.
Summary of studies and clinical trials on LAMB use for VL.
Table 5.
Injectable liposomal products approved by the US FDA.
Table 6.
Overview of LAMB formulations introduced in the market or under development*.
WHO. Technical Report Series (TRS), Annex 6 "Costs of medicines in current use for the treatment of leishmaniasis". 2010 Reithinger R, Dujardin JC, Louzir H, Cutaneous leishmaniasis. Lancet Infect Dis 2007;7(9):581-96 Wortmann G, Zapor M, Ressner R, Liposomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83(5):1028-33 Motta JO, Sampaio RNR. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2012;26:331-5 Amato VS, Tuon FF, Siqueira AM, Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007;77(2):266-74 Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev Soc Bras Med Trop 1997;30(2):125-8 Amato VS, Tuon FF, Camargo RA, Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011;85(5):818-19 Musa AM, Khalil EA, Mahgoub FA, Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005;99(6):563-9 Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011;53(12):e152-8 Sinha PK, van Griensven J, Pandey K, Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011;53(7):e91-8 Sundar S, Sinha PK, Rai M, Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377(9764):477-86 Sundar S, Sinha PK, Verma DK, Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg 2011;105(2):115-17 Sinha PK, Roddy P, Palma PP, Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 2010;83(2):357-64 Mondal S, Bhattacharya P, Rahaman M, A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Med 2010;4(7):e764 Sundar S, Chakravarty J, Agarwal D, Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362(6):504-12 Sundar S, Rai M, Chakravarty J, New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47(8):1000-6 Molina I, Falco V, Crespo M, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007;60(4):837-42 Mueller M, Ritmeijer K, Balasegaram M, Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007;101(1):19-24 Mueller M, Balasegaram M, Koummuki Y, A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006;58(4):811-15 Sanath SS, Gogtay NJ, Kshirsagar NA. Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: an Indian liposomal amphotericin B preparation. J Postgrad Med 2005;51(Suppl 1):S58-63 Kafetzis DA, Velissariou IM, Stabouli S, Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005;25(1):26-30 Cascio A, di Martino L, Occorsio P, A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother 2004;54(1):217-20 Sundar S, Mehta H, Suresh AV, Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004;38(3):377-83 Sundar S, Jha TK, Thakur CP, Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003;37(6):800-4 Pagliano P, Rossi M, Rescigno C, Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 2003;52(2):264-8 Syriopoulou V, Daikos GL, Theodoridou M, Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36(5):560-6 Sundar S, Jha TK, Thakur CP, Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002;66(2):143-6 Sundar S, Agrawal G, Rai M, Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323(7310):419-22 Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001;17(1):67-70 Bodhe PV, Kotwani RN, Kirodian BG, Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1999;93(3):314-18 Berman JD, Badaro R, Thakur CP, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998;76(1):25-32 di Martino L, Davidson RN, Giacchino R, Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997;131(2):271-7 Davidson RN, di Martino L, Gradoni L, Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22(6):938-43 Seaman J, Boer C, Wilkinson R, Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21(1):188-93 Davidson RN, Di Martino L, Gradoni L, Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87(2):75-81